Bioventus Inc. Income Statement
BVS|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Bioventus Inc. reported $568M in revenue and $23M in net income for FY2025. Revenue has grown at a 13.7% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $430.9M | $512.1M | $340.1M |
| Cost of Revenue | $179.9M | $185.1M | $128.2M | $181.0M | $90.9M |
| Gross Profit | $388.2M | $388.2M | $302.7M | $331.1M | $249.2M |
| SG&A Expense | $314.0M | $343.8M | $254.3M | $332.1M | $198.5M |
| R&D Expense | $12.1M | $14.0M | $19.0M | $23.9M | $11.1M |
| Operating Income | $54.0M | -$15.2M | $12.1M | -$167.2M | $31.2M |
| Income Tax | -$1.6M | -$5.3M | -$2.0M | -$44.4M | $1.6M |
| Net Income | $22.7M | -$36.1M | $19.4M | -$158.7M | $6.9M |
| EPS (Basic) | -$2.49 | -$2.59 | -$0.15 | -$0.15 | -$0.15 |
| EPS (Diluted) | -$2.49 | -$2.59 | -$0.15 | -$0.15 | -$0.15 |
| Shares Outstanding | 62.6M | 61.4M | 45.5M | 45.5M | 45.5M |
| Gross Margin | 68.3% | 67.7% | 70.3% | 64.6% | 73.3% |
| Operating Margin | 9.5% | -2.6% | 2.8% | -32.7% | 9.2% |
| Profit Margin | 4.0% | -6.3% | 4.5% | -31.0% | 2.0% |